Search

Within existing traceability systems for patient safety, the management of high risk drugs is a critical aspect. Among these, antineoplastic drugs are especially relevant. The traceability of these drugs in this project involves all processes of the oncological pharmacotherapeutic chain: e-prescription, pharmaceutical validation, preparation, dispensing and administration with bar code verification, and mutidisciplinary patient follow-up. After the implantation of new technologies, it is essential to perform both a technical evaluation of these such as the perceptions of their users, in this case nursing professionals and patients. Therefore, an observational study was performed one year after its implantation on the administration of cytostatics with bar code, in which 30% of observations with incidence were detected; of these, 42.5% were related to the operating procedure and 57.5% related to faults in the technology. The result of a safety perception study performed on patients one year after its implantation led to obtaining 95% feeling "total safety" and 4% "significant safety", with 1% remaining "indifferent"; when the study was repeated three years later, the percentages were 66.6% "total safety", 33.3% "significant safety" and any "indifferent". As for the study performed in 2010 to ascertain the opinion of nursing staff in regard to the safety of this administration system, 70% stated they "strongly agreed" and 30% "agreed"; 20% stated they had avoided a medication error thanks to the bar code. According to the results obtained in 2014, 69% "strongly agreed", 31% "agreed", and 31% had avoided an error. All this has led to the detection of possible faults, in addition to new actions to improve the system. These are always consensual and involve all participants. [ABSTRACT FROM AUTHOR]

Objective: To describe a compounding training plan in a tertiary hospital pharmacy service. The project aimed pharmacy assistant technicians to use a digital training platform and simulation techniques., Methods: Two training programs were designed, one for sterile and the other for non-sterile drugs. Each programme consists of several phases: a basic online training course (digital e-learning platform), a practical simulation workshop, a supervised practice in real conditions, and a final verification by the pharmacist to qualify the technician. Both programs include continuous and accredited evaluation by the hospital's Continued Education Commission. A satisfaction survey on training (e-lerning platform) was designed and conducted for pharmacy technicians (sterile and non-sterile)., Results: The project has been running for 3 years. Six specialist pharmacists from different areas involved in compounding are responsible for training and continuous evaluation. Twenty-one technicians have been trained, and nineteen have obtained qualifications. Two of them were found to be unfit. Currently, we employ13 pharmacy technicians who were initially trained. The participation rate in the satisfaction survey on training (e-learning platform) was 61.5% (n=8) out of a total number of current developers (n=13). Overall, 62.5% of technicians reported being satisfied or very satisfied, while the remaining 37.5% were indifferent., Conclusions: Compounding training program is currently in its third year. It has been crucial in delegating tasks to pharmacy technicians. The use of digital technology is essential in this training. We consider that, specific training in compounding, is indispensable and should be included in the academic plan for pharmacy technicians., Competing Interests: Declaration of Competing Interest None declared., (Copyright © 2023 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.)

Objective: To describe a compounding training plan in a tertiary hospital Pharmacy Service. The project aimed to train Pharmacy Assistant Technicians using a digital training platform and simulation techniques., Methods: Two training programmes were designed, one for sterile and the other for non-sterile drugs. Each programme consists of several phases: a basic online training course (digital e-learning platform), a practical simulation workshop, a supervised practice in real conditions and a final examination by the pharmacist to qualify the technician. Both programmes include a continuous and accredited evaluation by the hospital's Continuing Education Commission. A satisfaction survey on training (e-learning platform) was designed and conducted for pharmacy technicians (sterile and non-sterile)., Results: The project has been running for three years. Six specialist pharmacists from the different areas involved in compounding are responsible for training and continuous evaluation. Twenty-one technicians were trained, 19 were qualified, and two of them were unsuccessful. Nowadays, we have 13 pharmacy technicians out of those who were originally trained. Participation in the training satisfaction survey (e-learning platform) was 61.5% (n = 8) of the total number of current developers (n = 13). Overall satisfaction was good with 62.5% of technicians satisfied or very satisfied and the remainder were indifferent (37.5%)., Conclusions: The compounding training program is now in its third year. It has been crucial in delegating tasks to Pharmacy technicians. The use of digital technology is essential in training. We believe that specific training in compounding, is essential and should be included in the pharmacy technician curriculum., (Copyright © 2023. Publicado por Elsevier España, S.L.U.)

Objectives: To compare the outcomes of treosulfan-based vs busulfan-based conditioning regimens in allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients., Methods: Retrospective study of all consecutive patients (2012-2019) treated with allogenic HSCT and treosulfan- or busulfan-based conditioning regimens at a single center., Results: A total of 101 HSCT were included: 66 HSCT with busulfan and 35 with treosulfan. In malignant diseases (n = 62), busulfan-based conditioning was more commonly employed than treosulfan: 82.3% vs 17.7%. However, the use of treosulfan for malignant diseases increased over time: 6.5% of HSCT in 2012-2015 vs 29% of HSCT in 2015-2019 (p = .02). The cohort of treosulfan had more children under 1-year of age than the busulfan cohort (31 vs 13%; p = .033). The percentage of patients who received serotherapy was 73 and 89% in the nonmalignant and malignant groups, respectively. The engraftment, time to neutrophil, and platelet engraftment were not significantly different between the busulfan and the treosulfan cohorts. Rate of grade II-IV acute GvHD was significantly higher in the busulfan cohort than the treosulfan cohort (39% vs 15%; p = .016). No differences were observed in endothelial damage complications, chronic GvHD, relapse, overall survival, and transplant-related mortality., Conclusions: Busulfan-based conditioning regimens are used more frequently for children undergoing allogenic HSCT, but treosulfan-based conditioning is gaining acceptance. Treosulfan-based conditioning is associated with lower rates of acute GvHD, and no significant differences on overall survival were observed compared with busulfan., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Objective: The purpose of this article is to describe the PeOpLe study protocol, developed to assess patient-reported health outcomes in  advanced or metastatic non-small-cell lung cancer in routine clinical practice using the methodology provided by the International Consortium for Health Outcomes Measurement tool., Method: The study envisaged will be multicenter, longitudinal, ambispective and observational. Two groups will be compared: a control group (followed up according to standard clinical practice) and an experimental group (followed up using the International Consortium for Health  Outcomes Measurement methodology adapted to the Spanish setting for 6  months). The variables collected will be related to demography (age, sex,  degree of family support), clinical factors (smoking, comorbidities, lung  capacity), the neoplasm (histology, staging, mutations), pharmacotherapy  (treatment schedule, modifications, and complications), health status  (functional status, quality of life, satisfaction and overall survival) and resource consumption (emergency visits, hospital admissions and time spent by health providers). The PeOpLe study protocol has been approved by the Ethics Committee for Research into Medicinal Products of the Gregorio Marañón General University Hospital and will be conducted in compliance with prevailing ethical principles and standards., Conclusions: The PeOpLe study will explore how patient-reported outcomes collection can be developed and integrated with the clinical processes used in  the management of patients with locally advanced or metastatic nonsmall cell  lung cancer what patient-reported outcomes can be measured with systems  that can conveniently be used both by patients and by healthcare providers.  Systematic evaluation of patient-reported outcomes will help determine their  impact in terms of effectiveness (survival), safety (complications of systemic  therapy), and quality of life and patient satisfaction. The multidisciplinary and  multicenter nature of the study will facilitate a comprehensive view of the  subject analyzed and allow external reproducibility., (Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.)

The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome., (© 2020 British Society for Haematology and John Wiley & Sons Ltd.)